Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 10

563P - The impact of participation in colorectal cancer screening: A population-based results from Lithuania

Date

21 Oct 2023

Session

Poster session 10

Topics

Tumour Site

Colon and Rectal Cancer

Presenters

Tomas Poskus

Citation

Annals of Oncology (2023) 34 (suppl_2): S410-S457. 10.1016/S0923-7534(23)01935-X

Authors

T. Poskus1, M. Jakubauskas1, L. Jakubauskiene2, C. William Thattakath3, E. Jasiunas4, K. Strupas1

Author affiliations

  • 1 Clinic Of Gastroenterology, Nephrourology And Surgery, Institute Of Clinical Medicine, Vilnius University - Faculty of Medicine, 03101 - Vilnius/LT
  • 2 Clinic Of Obstetrics And Gynecology, Institute Of Clinical Medicine, Vilnius University - Faculty of Medicine, 03101 - Vilnius/LT
  • 3 Faculty Of Medicine, Vilnius University - Faculty of Medicine, 03101 - Vilnius/LT
  • 4 Center Of Informatics And Development,, Vilnius University Hospital Santaros Klinikos, 08410 - Vilnius/LT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 563P

Background

Around 1.9 million new cancer cases and around 930,000 deaths were attributed to colorectal cancer (CRC) worldwide in 2020. The European Union recommends population-based CRC screening. Reported long‘term results from various CRC screening programs are quite controversial as some of them report no survival gains. In June 2009 the CRC screening program was initiated in Lithuania. The aim of the study is to report the impact of CRC screening program on long-term mortality.

Methods

The anonymous data of the population aged 50-74 from the years 2013 to 2019, who participated in the CRC screening program were extracted from the statistical database of the National Health Insurance Fund, which provided both, the participation in different services of screening indicated by specific codes, and the mortality and survival marked in the database. For statistical analysis we divided patients in three groups: Negative fecal immunochemical test (FIT); positive FIT and screening colonoscopy performed; positive FIT and screening colonoscopy was not performed. The statistical analysis was performed using the R statistical software package v4.2.2.

Results

From the year 2013 to 2019 a total of 1,521551 people participated in the screening program. During the observation period 66920 (4.4%) patients died. The highest mortality was seen in patients that were diagnosed with cancer (19%). High mortality was seen in patients that did not proceed with further colonoscopy after a positive FIT. These patients had a significantly higher mortality rate: Negative FIT (4.2%) vs. Positive FIT + colonoscopy (4.9%) vs. Positive FIT - colonoscopy (8.6%); p<0.001. A univariate logistic regression analysis revealed that positive FIT + colonoscopy (OR 1.19 95% CI 1.15-1.24; p<0.001) and positive FIT - colonoscopy (OR 2.18 95% CI 2.12-2.24; p<0.001) groups had significantly increased mortality risks when compared to the negative FIT group.

Conclusions

Fully completed screening after a positive FIT result is associated with significantly reduced mortality.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.